Glial expression of tumor necrosis factor in transgenic animals: How do these models reflect the "normal situation"?

GLIA

Volumn 36, Issue 2, 2001, Pages 212-219

  Probert, Lesley ^a   Akassoglou, Katerina ^b  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Autoimmune; Demyelination; Multiple sclerosis; TNF; TNF receptors

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; CENTRAL NERVOUS SYSTEM; DISEASE MODEL; ENCEPHALITIS; GLIA; HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; ENCEPHALITIS; HUMANS; MULTIPLE SCLEROSIS; NEUROGLIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035148983     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.1110     Document Type: Article

References (71)

1. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice
2. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: Models for multiple sclerosis with primary oligodendropathy
3. Transgenic models of TNF induced demyelination
4. Impairment of TNF-receptor-1 signaling but not Fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice
5. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins
6. An essential role for NF-κB in preventing TNF-α-induced cell death
7. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling
8. Regulation of autoimmunity by proinflammatory cytokines
9. Differential susceptibility of human CNS-derived cell populations to TNF-α-dependent immune-mediated injury
10. Differential expression, cytokine modulation, and specific functions of type-1 and type-2 tumor necrosis factor receptors in rat glia
11. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin α, or the p55TNF-R
12. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
13. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity
14. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1
15. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice
16. Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis
17. Danger signals: SOS to the immune system
18. Interferon beta-1b treatment modulates TNFα and IFNγ spontaneous gene expression in MS
19. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor
20. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells
21. Tumor necrosis factor identified in multiple sclerosis brain
22. Prevention of diabetes in nonobese mice by tumor necrosis factor (TNF): Similarities between TNF-α and interleukin 1
23. Astrocytes induce blood-brain barrier characteristics in cerebral endothelial cells
24. Allele-specific quantitation of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals
25. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p56 TNF receptor level. Implications for pathogenesis and therapy of autoimmune demyelination
26. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis
27. A tumor necrosis factor-induced model of human primary demyelinating diseases develops in immunodeficient mice
28. Tumor necrosis blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system
29. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting
30. The -308 tumor necrosis factor-α promoter polymorphism effects transcription
31. Remyelination in multiple sclerosis
32. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
33. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
34. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria
35. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis
36. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases
37. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
38. Characterization of tumor necrosis factor-deficient mice
39. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria
40. Immunological tolerance to a pancreatic antigen as a result of local expression of TNFα by islet β cells
41. Cytokines in inflammatory brain lesions: Helpful and harmful
42. Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response
43. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation
44. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha
45. Multiple sclerosis: Expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque
46. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis
47. The genetic analysis of multiple sclerosis
48. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro
49. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I
50. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions
51. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis
52. Innate immunity and autoimmunity: From self-protection to self-destruction
53. The central nervous system as an immunocompetent organ: Role of glial cells in antigen presentation
54. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor
55. A critical role for lymphotoxin in experimental allergic encephalomyelitis
56. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice
57. The two different receptors for tumor necrosis factor mediate distinct cellular responses
58. A novel domain within the 55 kd TNF receptor signals cell death
59. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor
60. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-α in the central nervous system
61. The pathophysiology of tumor necrosis factors
62. Suppression of TNF-α-induced apoptosis by NF-κB
63. Two tumour necrosis factor receptors: Structure and function
64. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
65. Cell death induction by receptors of the TNF family: Towards a molecular understanding
66. The ligands and receptors of the lymphotoxin system
67. Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays
68. Effects of a polymorphism in the human tumor necrosis α promoter on transcriptional activation
69. Tumor necrosis factor
70. Induction of apoptosis in mature T cells by tumour necrosis factor
71. + T cells